Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

TLDR

The complete NCCN Guidelines also cover nonurothelial histologies and nonbladder urinary tract cancers such as upper tract urothelial carcinoma, urothelial carcinoma of the prostate, and primary urethral carcinoma. This selection of the NCCN Guidelines focuses on the clinical presentation, workup, and treatment of non‑muscle‑invasive and metastatic urothelial bladder cancer, highlighting recent updates. Updates include guidance for optimal treatment during a BCG shortage, biomarker testing for advanced disease, and coverage of muscle‑invasive, nonmetastatic disease in the full guidelines. Systemic therapy recommendations for second‑line or subsequent treatments have been revised.

Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non–muscle-invasive urothelial bladder cancer, and treatment of metastatic urothelial bladder cancer because important updates have recently been made to these sections. Some important updates include recommendations for optimal treatment of non–muscle-invasive bladder cancer in the event of a bacillus Calmette-Guérin (BCG) shortage and details about biomarker testing for advanced or metastatic disease. The systemic therapy recommendations for second-line or subsequent therapies have also been revised. Treatment and management of muscle-invasive, nonmetastatic disease is covered in the complete version of the NCCN Guidelines for Bladder Cancer available at NCCN.org . Additional topics covered in the complete version include treatment of nonurothelial histologies and recommendations for nonbladder urinary tract cancers such as upper tract urothelial carcinoma, urothelial carcinoma of the prostate, and primary carcinoma of the urethra.